Palazestrant

Palazestrant is an orally available, small molecule antagonist of estrogen receptor alpha (ERalpha; ERa; ESR1; nuclear receptor subfamily 3, group A, member 1; NR3A1) and a selective ER degrader (SERD), with potential antineoplastic activity. Upon oral administration, palazestrant competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket of ERalpha, thereby inhibiting the activity of ERalpha. Palazestrant blocks estrogen-driven transcriptional activity and induces degradation of ERalpha. This inhibits the growth and survival of ERalpha-expressing cancer cells. ERalpha, a nuclear hormone receptor, is often overexpressed and/or mutated in a variety of cancer cell types. It plays a key role in tumor cell proliferation and survival. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include OP-1250, 1H-Pyrido[3, 4-b]indole, 2-(2-fluoro-2-methylpropyl)-2, 3, 4, 9-tetrahydro-3-methyl-1-[4-[(1-propyl-3-azetidinyl)oxy]phenyl]-, (1R and 3R)-. Its PubChem CID is 135351887.

CAS No 2092925-89-6
Molecular Formula C28H36FN3O
Molecular Weight 449.6 g/mol
Synonyms (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole

Frequently Asked Questions